Clene

Clene Operating Expenses

The Total Operating Expenses of Clene (CLNN) as of Nov 16, 2026 is 23.24 M USD. In the previous year, Total Operating Expenses was 33.37 M USD — a change of -30.35% (lower).

Operating Expenses

23.24 MUSD

YoY

-30.35%

Last updated:

Total Operating Expenses of Clene is 2025 23.24 M USD. Total Operating Expenses of Clene was 2024 33.37 M USD. It decreases by -30.35% lower compared to the previous year.

The Clene Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
9.16 M USD
Jan 1, 2019
15.53 M USD
Jan 1, 2020
18.47 M USD
Jan 1, 2021
47.23 M USD
Jan 1, 2022
48.08 M USD
Jan 1, 2023
41.07 M USD
Jan 1, 2024
33.37 M USD
Jan 1, 2025
23.24 M USD
The Clene Operating Expenses history
YEAROperating ExpensesYoY
23.24 MUSD-30.35%
33.37 MUSD-18.77%
41.07 MUSD-14.58%
48.08 MUSD+1.81%
47.23 MUSD+155.76%
18.47 MUSD+18.89%
15.53 MUSD+69.56%
9.16 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Total Operating Expenses of Clene is 23.24 M USD in 2025.

Total Operating Expenses of Clene changed from 33.37 M USD to 23.24 M USD, representing a -30.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Clene since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Clene

All Key Metrics — Clene